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estern Paciﬁc, Americas, Epidemiology
a  b  s  t  r  a  c  t
Tremendous  progress  has  been  made  globally  to reduce  the  contribution  of measles  to  the  burden  of
childhood  deaths  and  measles  cases  have  dramatically  decreased  with increased  two  dose  measles-
containing  vaccine  coverage.  As  a result  the Global  Vaccine  Action  Plan,  endorsed  by the World  Health
Assembly,  has  targeted  measles  elimination  in  at least  ﬁve  of the  six  World  Health  Organisation  Regions  by
2020. This  is an  ambitious  goal,  since  measles  control  requires  the  highest  immunisation  coverage  of  any
vaccine  preventable  disease,  which  means  that  the  health  system  must  be able  to reach  every  community.
Further,  while  measles  remains  endemic  in any country,  importations  will result  in local  transmission
and  outbreaks  in  countries  and Regions  that have  interrupted  local  endemic  measles  circulation.
One of  the lines  of evidence  that  countries  and Regions  must  address  to conﬁrm  measles  elimination
is  a detailed  description  of  measles  epidemiology  over  an extended  period.  This information  is incredi-
bly  valuable  as  predictable  epidemiological  patterns  emerge  as  measles  elimination  is approached  and
achieved.  These  critical  features,  including  the source,  size  and  duration  of outbreaks,  the  seasonality  and
age-distribution  of  cases,  genotyping  pointers  and  effective  reproduction  rate  estimates,  are  discussed
with  illustrative  examples  from  the  Region  of  the  Americas,  which  eliminated  measles  in 2002,  and  the
Western  Paciﬁc  Region,  which  has  established  a Regional  Veriﬁcation  Commission  to review  progress
towards  elimination  in all member  countries.
Crown  Copyright  © 2014  Published  by Elsevier  Ltd.  This  is  an  open  access  article  under  the
CC. Background
Global measles control has been very successful. Estimated
eaths fell by 74% from 535,300 in 2000 to 139,300 in 2010 [1].
ndeed reductions in measles mortality accounted for 23% of the
stimated decline in all-cause child mortality in children under 5
ears of age from 1990 to 2008 [2].
The initial strategy of a measles immunisation program is
easles control; once this is achieved the focus shifts to outbreak
revention, elimination and ﬁnally eradication. In 2010, an expert
dvisory committee was convened by the World Health Organi-
ation (WHO) to assess the feasibility of measles eradication. The
anel determined that eradication was indeed biologically, techni-
ally and operationally feasible; and concluded that measles can
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and should be eradicated using activities to strengthen routine
immunisation services [3–5].
2. The goal of measles elimination
The WHO  Global Vaccine Action Plan for 2012–2020 has
established the target of measles and rubella elimination in
at least ﬁve WHO  Regions by 2020 and Member States in
all six Regions have established goals to eliminate measles by
2020 or before [6]. Elimination is deﬁned as “the absence of
endemic measles transmission in a deﬁned geographical area,
in this case all countries in a WHO  Region, for ≥12 months in
the presence of a well-performing surveillance system” [7]. To
verify that elimination has been achieved three essential cri-
teria must be met: the interruption of endemic measles virus
transmission for a period of at least 36 months from the
last known endemic case; in the presence of a high-quality
surveillance system that is sensitive and speciﬁc enough to
detect imported and import-related cases; and genotyping evi-
dence should support interruption. Detailed evidence across ﬁve
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omains must be presented to substantiate an individual coun-
ry or Region’s claim of having interrupted endemic measles
ransmission: a detailed description of measles epidemiology
ver an extended period; indicators of the quality of epidemi-
logical and laboratory surveillance; measures of population
mmunity by birth cohort; laboratory evidence of absence of an
ndemic genotype; and conﬁrmation of immunisation programme
ustainability.
The elimination of endemic measles transmission was achieved
n the Region of the Americas in 2002 and sustained for more than a
ecade despite ongoing incursions of virus from other parts of the
orld [8]. This remarkable achievement has led to many lessons
earnt and given impetus to achieving elimination in other Regions.
he Region of the Americas was the ﬁrst region to eliminate polio,
nd is now leading the way with measles. The experience has also
ighlighted the ongoing challenges involved in sustaining elimina-
ion – measles anywhere is a problem everywhere. By May  2014 the
SA had experienced more cases of measles than in any whole year
ince elimination was achieved, linked to importations and subse-
uent outbreaks [9]. Brazil and Canada have also experienced large
utbreaks this year [10].
An independent International Expert Committee (IEC) was
stablished by the Pan American Health Organization in 2010 with
he purpose of documenting the elimination of measles, rubella
nd congenital rubella syndrome in the Region of the Ameri-
as, and has not yet reported its conclusions. During the period
f the IEC deliberations, several measles outbreaks occurred that
ere brought under control. In 2011 Canada experienced the
argest outbreak of measles the Region had seen since elimina-
ion. This was linked to multiple importations into Quebec from
 large outbreak in France but brought under control within 12
onths, so that endemic transmission was not re-established
11]. The experience of this and several other outbreaks have
nderlined the importance of not only having elimination-level
overage of greater than 95% to ensure population immunity lev-
ls reach 95%, but also of ensuring the quality of coverage data
t every administrative level. Outbreaks in marginalised com-
unities, including Aboriginal peoples, have demonstrated the
ecessity of reaching every community [12,13]. The Caribbean
as successfully protected its population from measles and sus-
ained elimination despite receiving large numbers of tourists,
any coming from other Regions where measles is not con-
rolled. Haiti, for example, demonstrates how determination and
olitical will enabled elimination to be achieved in the face of
ultiple major challenges including recurrent natural disasters
14].
In the Western Paciﬁc region, encouraging progress was made
n recent years with coverage of one dose of measles-containing
accine increasing from 85% in 2000 to 97% within a decade and
eported second routine dose coverage reaching 91% [15]. The
argest supplementary immunisation activity in history was con-
ucted in China in 2010, with over 103 million children vaccinated.
he results of these activities were reﬂected in a 91% reduction in
eported measles cases between 2000 and 2011, and an estimated
4% reduction in deaths between 2000 and 2012 [16]. However, the
estern Paciﬁc is experiencing an increase in measles incidence
hich started in 2013 and has continued through mid-2014 with
ngoing outbreaks in China, The Philippines, Vietnam and Papua
ew Guinea [17].
As the Americas and Western Paciﬁc have achieved and sus-
ained or made progress towards measles elimination, distinctive
ommon epidemiological patterns have emerged across remark-
bly diverse populations conﬁrming theoretical predictions. These
hared features, which appear synonymous with elimination,
rovide a template that individual countries striving towards elim-
nation can apply to judge their own progress. 32 (2014) 6880–6883 6881
3. Incidence rates may  be misleading
Although the absence of locally acquired measles cases within
a country with sensitive surveillance is a wonderful aspiration,
this is generally only achieved by countries that are isolated or
remote and having few international travel movements to and
from measles-endemic countries. Mongolia and many remote
island countries in the Western Paciﬁc have enjoyed this expe-
rience for a number of years [18]. However, while measles is
endemic anywhere in the world and the current scale of inter-
national travel is maintained, the integrity of most countries’
population immunity will be regularly tested by importation of
measles virus in non-immune residents returning from endemic
areas or infectious visitors from endemic areas. An indicative inci-
dence rate was nominated by the WHO  as a milestone towards
achieving elimination. This was set at less than one laboratory
or epidemiologically conﬁrmed measles case per million popu-
lation annually; excluding imported cases [19]. However, once
a country succeeds in eliminating measles, this indicator is no
longer helpful. For countries with relatively large numbers of
visitors and local international travellers compared to their pop-
ulation denominator, for example Australia and countries of the
Caribbean, despite interrupting endemic measles transmission this
indicator may  still be regularly exceeded because of multiple
short chains of local transmission following importations [20]. In
that situation, the classiﬁcation of cases as imported or import-
related (for onward transmission) is the key to documenting that
elimination is being sustained. If chains of transmission extend
beyond 12 months, then measles is by deﬁnition no longer elimi-
nated.
4. Sleuthing the source of infection
Of much greater value than incidence is the early detection
and careful categorisation of all measles cases by their source of
infection; “imported”, “import-related”, “endemic” or “unknown”
[19,21]. Ideally 80% or more of all conﬁrmed measles cases should
be “imported” or “import-related”. In the Western Paciﬁc, this was
achieved by the three countries with measles activity that were
recently veriﬁed as having interrupted endemic measles transmis-
sion; Australia, Macao (Special Administrative Region of China), and
the Republic of Korea. The fourth country Mongolia had experi-
enced no measles cases for a four year period and had consistently
detected and investigated an adequate number of rash and fever
cases to exclude measles. This vouched for the sensitivity of their
surveillance.
The ability to categorise measles source for the majority of
cases reﬂects the thoroughness and timeliness of epidemiological
investigation, including the submission of appropriate specimens
to permit laboratory conﬁrmation of cases, while simultaneously
revealing the integrity of herd immunity. Where a large propor-
tion of cases are of “unknown” origin it is challenging to conﬁrm
that ongoing local transmission is not occurring. All “unknown”
source cases need to be carefully analysed temporally and spatially
at local level in an attempt to rule out ongoing chains of transmis-
sion [22]. This cluster mapping should assess possible overlapping
infectious and incubation periods of subsequent detected cases. In
these instances genotyping of unknown source cases can assist in
distinguishing the likely origin/s of virus.
5. Epidemic curves – barometers of progress towards
elimination at every level
Epidemic curves are most commonly used to understand
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onitoring the success of any control measures implemented.
hey have an additional important utility. Applying this epidemi-
logical tool at various resolutions (sub-national, national and
egional) over multiple years following the introduction of measles
ontaining vaccine provides useful complementary evidence of
rogress towards elimination [23]. In highly endemic situations
arge measles epidemics occur in cycles with a 1–4 year period-
city and with a deﬁned seasonal pattern even in inter-epidemic
ears. As higher uniform population immunity is achieved the
cale of epidemics, both their duration and absolute number
f cases, progressively decreases. Epidemic frequency simultane-
usly decreases with increasing time intervals between epidemics.
nother uniform feature as elimination is approached is the loss of
pidemic seasonality.
. The canary in the coalmine
As will be seen in the discussion of reproduction num-
ers below, measles is incredibly infectious. This transmissibility
f measles allows immunity gaps to be revealed; measles
erving as the sensitive “canary in the coalmine” detecting
eﬁciencies in vaccination coverage, pockets of susceptible indi-
iduals, vaccine refusers or marginalised groups, and causing
ultiple generations of infection where coverage is inade-
uate.
Measles outbreaks are our instructor; if they are carefully
nalysed by the demographic characteristics of those affected,
ncluding their location, age group, social, cultural, religious and
thnic features, they reveal population pockets or age cohorts vul-
erable to measles because of inadequate immunity. Outbreaks can
inpoint communities with geographical or shared socio-cultural
eatures that are consistently missing out on the beneﬁts of measles
accine. This may  be the result of health service failure to pro-
ide equitable access to child health programmes or resistance
gainst immunisation by deﬁned groups. Both Canada and Australia
ave seen examples of religious groups with inadequate vaccina-
ion coverage serving as the launch pad for international measles
ransmission [9,24–26].
Where measles epidemiology points to broader community
mmunity gaps by age cohort or locality, this knowledge may
e supplemented or conﬁrmed by conducting serological surveys
f measles immunity and then applied to creatively ﬁll diag-
osed immunity gap/s. A good example comes from the recent
xperience of Japan. After a large outbreak in 2007 and 2008
articularly affecting teenagers, a catch-up measles vaccination
rogram was introduced in two school years, the ﬁrst year of
unior high school (12–13 years) and the third year of high school
17–18 years) from 2008 to 2012 [27]. This effectively plugged the
mmunity gap revealed by the outbreak and conﬁrmed serologi-
ally.
The nature of outbreaks can also highlight health service deﬁ-
iencies permitting the spread of measles amongst vulnerable
on-immune groups. This was a particular feature of recent out-
reaks in a number of countries that have interrupted endemic
easles transmission, including the Republic of Korea, Australia
nd the USA [28–30]. A common feature of these outbreaks was
easles predominantly occurring in young children, most too
oung to be immunised or only having received a single measles
accine dose, with nosocomial spread due to deﬁciencies in infec-
ion control. In all cases measures were taken to strengthen triage
nd isolation practices, and promote the vaccination of health care
taff. Compared with polio, elimination of measles relies more
eavily on strong routine services both because of the requirement
o reach all communities with such high coverage, and because the
accine is delivered by injection. 32 (2014) 6880–6883
7. Estimating R0 and Re
A valuable epidemiological measure of an infectious agent’s
transmissibility is its basic reproduction number (R0) – the aver-
age number of secondary cases generated by a primary case in
a completely susceptible population. Measles is the most infec-
tious communicable disease known with a R0 of 12–18 [31,32]. This
infectiousness poses a massive challenge to elimination as in most
settings 95% or more of the population will need to be immune to
ensure adequate herd immunity to prevent or contain outbreaks
following introduction of virus, and allowing for vaccine effective-
ness of 90%, coverage needs to be even higher. Herd immunity can
be thought of as a threshold level of immunity in the population
above which measles no longer spreads, mathematically calculated
from R0.
As has been discussed, individual outbreaks are enormously
informative but the collective wisdom gained from an analy-
sis of the distribution of outbreak sizes and their duration (or
generations of infection resulting from each imported case) can
provide a further measure of the robustness of elimination and
the effective reproduction number, Re, which is the actual aver-
age number of secondary cases that result from an infectious
case in a particular population. Re depends on the level of
susceptibility in the population, in contrast to the basic repro-
duction number (R0), which is the average number of secondary
cases arising from one infectious case in a totally susceptible
population [33]. Well established methods exist to estimate Re
from outbreak data and these have been applied in the United
States, Canada and Australia [34–36]. During the elimination sce-
nario, where the proportion of susceptibles is sufﬁciently low
that sustained transmission is not possible, the vast majority
of outbreaks are small in size (single digit number of sec-
ondary cases) and there are on average few generations of
spread, with Re sustained well below the epidemic threshold of
1.
These methods can be utilised over time to monitor trends and
can also be applied to birth cohorts and at subnational level, with
adequate conﬁdence levels, to explore for heterogeneity of risk [35].
Sero-surveys may  also provide useful data to provide estimates of
Re and signal the risk of impending outbreaks [37].
8. Elimination paradoxes
It is often disconcerting for public health programmes when
the majority of measles cases occur in children too young to
have received one or two doses of measles containing vaccine.
It is important to note that this generally represents a relative
increase in cases in this age-group and not an absolute increase.
The immediate temptation is to shift the lower recommended age
for vaccination to young infants. Although it may  be necessary in
speciﬁc situations, for example large outbreaks, to provide a sup-
plementary dose of vaccine at 6 months of age this should not
replace the dose provided from 8 to 12 months of age, as sero-
conversion and protection is signiﬁcantly lower during younger
infancy due to maternal antibody interference with the child’s
immune response to the vaccine [38].
Similarly measles incidence may  increase in older age groups
in absolute or relative terms, typically amongst adults or teenagers
who may  have been part of the ﬁrst birth cohorts to receive measles
containing vaccine. Generally programme coverage builds over
time and many programmes initiated measles vaccination with
only a single dose. Thus it is not surprising that there is often an
increased proportion of susceptibles in these age cohorts and a rel-
atively higher burden of infection amongst these individuals during
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A further conundrum is worth brief mention. IgM serology
emains as the backbone of measles laboratory conﬁrmation in
ost countries. Although these tests, performed in WHO  approved
aboratories, are generally excellent for programme purposes, like
ny test they are not 100% speciﬁc. In low prevalence elimina-
ion environments IgM serology will have a low positive predictive
alue, i.e. a considerable proportion of tests will provide false pos-
tive results. Indeed, if no measles cases are occurring, then all
ositive test results are expected to be false positives. Other diag-
ostic tests particularly immunoﬂuorescence, which may  be used
n the early phases of disease, is particularly prone to high false
ositivity. Guidelines have been developed to assist in the interpre-
ation of results in these settings but it is particularly important not
o view laboratory results in isolation from the clinical presentation,
ravel history and careful description of contact with possible cases
39].
. Conclusions
Measles’ transmission dynamics, particularly its infectiousness,
nd distinctive clinical picture result in predictable epidemiological
atterns as elimination is approached. There is no single indicator
f elimination. Careful analysis of the: source, size and duration of
utbreaks; genotyping, temporality and geography of “unknown
ource” cases; seasonality and age-distribution of cases; and effec-
ive reproduction rate provide a good indication of progress or
chievement of interruption of endemic transmission and the
ntegrity of population immunity. High quality coverage data are
ssential, at sub-national, district and even community levels, to
uide decision-making. Clearly the quality of epidemiological data
s dependent on the quality of surveillance and speciﬁcally the
arly investigation and conﬁrmation of suspected measles cases
40].
While the epidemiology may  be elegant it is critical that the
nderstandings extracted are applied for “action”. This is partic-
larly pertinent as measles is often not only a “canary in the
oalmine” for measles immunity gaps but more broadly reﬂects on
eﬁcits in child health programme access or health service delivery.
The elimination of measles brings additional beneﬁts through
trengthening health systems and better delivery of other vaccines
ncluding rubella. Measles will tell us quickly if we  are off track,
irect our efforts towards elimination and conﬁrm our arrival if we
llow its epidemiology to be our teacher.
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